Published in Antimicrob Agents Chemother on June 01, 2001
Antiparasitic agent atovaquone. Antimicrob Agents Chemother (2002) 1.41
Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model. Antimicrob Agents Chemother (2009) 1.05
Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis. Antimicrob Agents Chemother (2004) 1.01
Nanosuspension: An approach to enhance solubility of drugs. J Adv Pharm Technol Res (2011) 0.89
Nanoparticles containing insoluble drug for cancer therapy. Biotechnol Adv (2013) 0.86
Nanosizing of drugs: Effect on dissolution rate. Res Pharm Sci (2015) 0.86
Formulation and biopharmaceutical issues in the development of drug delivery systems for antiparasitic drugs. Parasitol Res (2002) 0.86
In vitro and in vivo activities of 1-hydroxy-2-alkyl-4(1H)quinolone derivatives against Toxoplasma gondii. Antimicrob Agents Chemother (2009) 0.85
The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice. Parasitol Res (2007) 0.78
Solid Lipid Nanoparticles of Atovaquone Based on 2(4) Full-Factorial Design. Iran J Pharm Res (2015) 0.77
Preventive effect of pidotimod on reactivated toxoplasmosis in mice. Parasitol Res (2013) 0.75
Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications. Parasitol Res (2017) 0.75
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
Toxoplasmic encephalitis in AIDS. Clin Infect Dis (1992) 7.64
Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med (1992) 6.30
Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell (1996) 4.74
AIDS commentary. Toxoplasmic encephalitis. J Infect Dis (1988) 4.14
Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev (1998) 4.03
Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med (1993) 2.78
Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother (1991) 2.56
Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis (1991) 2.04
Toxoplasma gondii infection of the central nervous system. Use of the peroxidase-antiperoxidase method to demonstrate toxoplasma in formalin fixed, paraffin embedded tissue sections. Hum Pathol (1981) 1.81
Toxoplasmosis in the non-AIDS immunocompromised host. Curr Clin Top Infect Dis (1993) 1.80
In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob Agents Chemother (1992) 1.72
Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction. J Exp Med (1997) 1.64
Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol (1994) 1.63
In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. Eur J Clin Microbiol Infect Dis (1991) 1.50
Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis (1996) 1.40
Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. J Infect Dis (1991) 1.33
The ketolide antibiotics HMR 3647 and HMR 3004 are active against Toxoplasma gondii in vitro and in murine models of infection. Antimicrob Agents Chemother (1997) 1.30
Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis (1993) 1.27
Rifabutin is active in murine models of toxoplasmosis. Antimicrob Agents Chemother (1994) 1.25
In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. Antimicrob Agents Chemother (1993) 1.23
Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis. Antimicrob Agents Chemother (1992) 1.15
The hematologic toxicity of pyrimethamine (daraprim) in man. Arch Ophthalmol (1960) 1.13
Induction of tumor necrosis factor-alpha and inducible nitric oxide synthase fails to prevent toxoplasmic encephalitis in the absence of interferon-gamma in genetically resistant BALB/c mice. Microbes Infect (2000) 1.00
Nanosuspensions of poorly soluble drugs--reproducibility of small scale production. Int J Pharm (2000) 0.98
Evaluation of the policy of empiric treatment of suspected Toxoplasma encephalitis in patients with the acquired immunodeficiency syndrome. Am J Med (1989) 0.96
High-performance liquid chromatographic assay for the measurement of atovaquone in plasma. J Chromatogr (1994) 0.96
Rifapentine is active in vitro and in vivo against Toxoplasma gondii. Antimicrob Agents Chemother (1996) 0.95
566C80, an antimalarial hydroxynaphthoquinone with broad spectrum: experimental activity against opportunistic parasitic infections of AIDS patients. J Protozool (1992) 0.95
Determination of the potent antiprotozoal compound atovaquone in plasma using liquid-liquid extraction followed by reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl (1996) 0.89
Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Drugs (1995) 0.87
Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate. J Parasitol (1993) 0.86
An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii. Int J Exp Pathol (1994) 0.85
Intracerebral toxoplasmosis in patients with acquired immune deficiency syndrome. J Neurosurg (1983) 0.80
Rapid high-performance liquid chromatographic assay for atovaquone. J Chromatogr B Biomed Appl (1996) 0.80
Ketolide ABT-773 is active against Toxoplasma gondii. J Antimicrob Chemother (2000) 0.79
Effect of solid lipid nanoparticles (SLN) on cytokine production and the viability of murine peritoneal macrophages. J Microencapsul (2001) 0.78
Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis. Parasite (1998) 0.78
Synergistic combination of azithromycin and sulfadiazine for treatment of toxoplasmosis in mice. Eur J Clin Microbiol Infect Dis (1992) 0.77
Toxoplasmosis. Lancet (2004) 13.96
The role of cell-mediated immunity in bacterial infections. Rev Infect Dis (1982) 9.26
Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science (1993) 4.53
Pharmacokinetics of ciprofloxacin after oral and parenteral administration. Antimicrob Agents Chemother (1985) 4.07
Biological functions of t cell lines with specificity for the intracellular bacterium Listeria monocytogenes in vitro and in vivo. J Exp Med (1982) 3.52
Specific Lyt 123 cells are involved in protection against Listeria monocytogenes and in delayed-type hypersensitivity to listerial antigens. J Exp Med (1979) 3.31
Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc Natl Acad Sci U S A (2001) 3.28
Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother (1987) 3.09
Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev (2001) 3.07
Endothelial apoptosis in Braf-deficient mice. Nat Genet (1997) 2.77
Immunohistochemical and electron microscopic study of interaction of Yersinia enterocolitica serotype O8 with intestinal mucosa during experimental enteritis. Infect Immun (1989) 2.60
T-cell subsets in delayed-type hypersensitivity, protection, and granuloma formation in primary and secondary Listeria infection in mice: superior role of Lyt-2+ cells in acquired immunity. Infect Immun (1988) 2.55
Cardiotrophic effects of protein kinase C epsilon: analysis by in vivo modulation of PKCepsilon translocation. Circ Res (2000) 2.38
Utility of upright tilt-table testing in the evaluation and management of syncope of unknown origin. Am J Med (1991) 2.16
Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev (2004) 2.10
Interferon-gamma production by Listeria monocytogenes-specific T cells active in cellular antibacterial immunity. Eur J Immunol (1983) 2.06
Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol (1986) 2.00
Markers of foamy virus infections in monkeys, apes, and accidentally infected humans: appropriate testing fails to confirm suspected foamy virus prevalence in humans. AIDS Res Hum Retroviruses (1995) 1.92
Characterization of Bartonella henselae isolated from bacillary angiomatosis lesions in a human immunodeficiency virus-infected patient in Germany. Clin Infect Dis (1998) 1.87
Reduced enteral absorption of ciprofloxacin in the presence of antacids. Eur J Clin Microbiol (1985) 1.86
pH gating of ROMK (K(ir)1.1) channels: control by an Arg-Lys-Arg triad disrupted in antenatal Bartter syndrome. Proc Natl Acad Sci U S A (1999) 1.85
Exacerbation of murine ileitis by Toll-like receptor 4 mediated sensing of lipopolysaccharide from commensal Escherichia coli. Gut (2007) 1.85
Enhancement of Nitrate Reductase Activity by Benzyladenine in Agrostemma githago. Plant Physiol (1971) 1.84
Head-upright tilt-table testing in evaluation and management of the malignant vasovagal syndrome. Am J Cardiol (1992) 1.82
Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother (2000) 1.80
Multicentre study of a new enzymatic method of cholesterol determination. J Clin Chem Clin Biochem (1984) 1.77
Seroepidemiology of Toxoplasma gondii infection in general population in a northern Mexican city. J Parasitol (2010) 1.76
Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption. Int J Pharm (2000) 1.73
Differentiation of convulsive syncope and epilepsy with head-up tilt testing. Ann Intern Med (1991) 1.72
NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest. J Biol Chem (2000) 1.64
Kinetic analysis of cytokine gene expression in the livers of naive and immune mice infected with Listeria monocytogenes. The immediate early phase in innate resistance and acquired immunity. J Immunol (1992) 1.63
Functional analysis of human foamy virus accessory reading frames. J Virol (1993) 1.59
Diagnosis of extrapulmonary tuberculosis by Gen-Probe amplified Mycobacterium tuberculosis direct test. J Clin Microbiol (1996) 1.58
[Correlation of thromboplastin times in dicumarol treated patients using various preparations of thrombokinase]. Z Klin Chem Klin Biochem (1970) 1.53
Tilt table testing in the evaluation and management of athletes with recurrent exercise-induced syncope. Med Sci Sports Exerc (1993) 1.53
Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J Biomed Mater Res (1998) 1.51
Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells. Proc Natl Acad Sci U S A (1995) 1.51
pH-dependent gating of ROMK (Kir1.1) channels involves conformational changes in both N and C termini. J Biol Chem (1998) 1.50
Acquired resistance to Listeria monocytogenes is mediated by Lyt-2+ T cells independently of the influx of monocytes into granulomatous lesions. J Exp Med (1989) 1.50
H-2K-restricted granuloma formation by Ly-2+ T cells in antibacterial protection to facultative intracellular bacteria. J Immunol (1985) 1.50
Interleukin 2 induction in Lyt 1+ 23- T cells from Listeria monocytogenes-immune mice. Infect Immun (1982) 1.49
Interleukin 2 receptor in patients with localized and systemic parasitic diseases. Clin Exp Immunol (1988) 1.49
Contact allergy due to colophony (III). Sensitizing potency of resin acids and some related products. Contact Dermatitis (1989) 1.44
Anatomic changes in multiple brainstem nuclei after incremental, near-complete neurotoxic destruction of the pre-Bötzinger Complex in adult goats. Respir Physiol Neurobiol (2010) 1.44
Mechanisms of granuloma formation in murine Mycobacterium avium infection: the contribution of CD4+ T cells. Int Immunol (1996) 1.44
Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory conditions. Mol Cell Biol (2000) 1.44
Regulatory interactions between macrophages and T-cell subsets in Listeria monocytogenes-specific T-cell activation. Infect Immun (1982) 1.43
Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm (1999) 1.42
Pharmacodynamics of fluoroquinolones. Clin Infect Dis (1998) 1.42
[Antimicrobial therapy in neutropenia]. Dtsch Med Wochenschr (1997) 1.40
Azithromycin--review of key chemical, pharmacokinetic and microbiological features. J Antimicrob Chemother (1996) 1.40
Use of the polymerase chain reaction for diagnosis of ocular toxoplasmosis. Ophthalmology (1999) 1.40
Multiple-dose pharmacokinetics of ceftazidime and its influence on fecal flora. Antimicrob Agents Chemother (1983) 1.39
Safety and efficacy of liposomal amphotericin B in treating AIDS-associated disseminated cryptococcosis. J Infect Dis (1991) 1.38
Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis (2001) 1.37
Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm (2004) 1.37
Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst (1999) 1.36
Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy (2013) 1.35
IL-4 is protective against development of toxoplasmic encephalitis. J Immunol (1996) 1.34
Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice. Infect Immun (1997) 1.34
Dynamics of T cells of L3T4 and Ly 2 phenotype within granulomas in murine listeriosis. Clin Exp Immunol (1985) 1.33
Genetic variability and prevalence of Bartonella henselae in cats in Berlin, Germany, and analysis of its genetic relatedness to a strain from Berlin that is pathogenic for humans. J Clin Microbiol (2001) 1.32
Molecular diagnosis of sepsis: New aspects and recent developments. Eur J Microbiol Immunol (Bp) (2014) 1.30
Comparative pharmacokinetics of apalcillin and piperacillin. Antimicrob Agents Chemother (1984) 1.28
Amphotericin B. Appl Microbiol Biotechnol (2005) 1.28
Humoral and cellular defense against intestinal murine infection with Yersinia enterocolitica. Infect Immun (1991) 1.28
Evaluation of a commercial rRNA target amplification assay for detection of Mycobacterium tuberculosis complex in respiratory specimens. Eur J Clin Microbiol Infect Dis (1994) 1.28
Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface-modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis (1993) 1.27
Diagnosis of Torulopsis glabrata infection. Successful treatment of two cases. JAMA (1968) 1.27
Cerebral vasoconstriction during head-upright tilt-induced vasovagal syncope. A paradoxic and unexpected response. Circulation (1991) 1.25
Comparative pharmacokinetics of new quinolones. Drugs (1987) 1.22
Interaction of permeant and blocking ions in cloned inward-rectifier K+ channels. Biophys J (1998) 1.22
Human kinesin superfamily member 4 is dominantly localized in the nuclear matrix and is associated with chromosomes during mitosis. Biochem J (2001) 1.22
Reliability of drug history in analgesic users. Lancet (1984) 1.21
Carotid body denervation alters ventilatory responses to ibotenic acid injections or focal acidosis in the medullary raphe. J Appl Physiol (1985) (2004) 1.21
Production of macrophage-activating and migration-inhibition factors in vitro by serologically selected and cloned Listeria monocytogenes-specific T cells of the Lyt 1+2- phenotype. Infect Immun (1984) 1.21
Determination of apalcillin and its metabolites in human body fluids by high-pressure liquid chromatography. Antimicrob Agents Chemother (1982) 1.19
Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother (1996) 1.19
[Subjective refraction assessment. II: Monocular fine adjustment]. Ophthalmologe (2002) 1.18
Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Oncogene (2010) 1.17
Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. J Control Release (2002) 1.17
Cytokines in the induction and expression of T-cell-mediated granuloma formation and protection in the murine model of listeriosis. Immunol Rev (1997) 1.16
Seroepidemiology of Toxoplasma gondii infection in pregnant women in rural Durango, Mexico. J Parasitol (2009) 1.16
Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J Biol Chem (2000) 1.16
Determinants of invasion and survival of Yersinia enterocolitica in intestinal tissue. An in vivo study. Med Microbiol Immunol (1989) 1.16
Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticles. Biomaterials (1999) 1.16
Pleiotropic effects of sonic hedgehog on muscle satellite cells. Cell Mol Life Sci (2005) 1.15
Multiple cotton wool spots following bone marrow transplantation for treatment of acute lymphatic leukaemia. Br J Ophthalmol (1985) 1.15
Genetic evidence that Sil is required for the Sonic Hedgehog response pathway. Genesis (2001) 1.15
Seroepidemiology of Toxoplasma gondii infection in patients with vision and hearing impairments, cancer, HIV, or undergoing hemodialysis in Durango, Mexico. J Parasitol (2010) 1.15
Rapamycin and wortmannin enhance replication of a defective encephalomyocarditis virus. J Virol (1998) 1.13
Seroepidemiology of infection with Toxoplasma gondii in workers occupationally exposed to water, sewage, and soil in Durango, Mexico. J Parasitol (2010) 1.12
[Determining subjective refraction. III: Binocular balance, near vision eyeglasses]. Ophthalmologe (2002) 1.12
Impact of maternal body mass index on neonatal outcome. Eur J Med Res (2009) 1.12
Regular analgesic intake and the risk of end-stage renal failure. Am J Nephrol (1989) 1.12
Primary isolation of Mycobacterium tuberculosis on blood agar during the diagnostic process for cat scratch disease. Infection (1998) 1.12
Quantitative contributions of IgG, IgM and C3 to erythrophagocytosis and rosette formation by peritoneal macrophages, and anti-opsonin activity of dextran sulfate 500. Eur J Immunol (1976) 1.12